Search results for: Market Access
Filter search results
Published: OHE Study Projecting UK Medicines Expenditure
30 September 2013
…macro perspective. This makes it possible to base forecasts on what is most likely to change in the medicines market, e.g. the appearance of new products and the debut of…
Personalised Medicine: Economic Incentives for Evidence Generation
28 October 2013
…can reward bringing higher-quality tests to market. Realistic expectations about standards of evidence. Data collection before the launch of a drug or diagnostic is limited by a number of considerations;…
OHE Welcomes Charlesworth and Mays to its Editorial Board
14 January 2014
…of York. Anita Charlesworth joined the Nuffield Trust as Chief Economist in 2010 and leads the Trust’s work on health care financing and market mechanisms. Before that, she held posts…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
…both regulators and HTA entities. The number that are available on markets worldwide still is low, which means that experience with their assessment is limited. OHE convened a one-day roundtable…
2014 Annual Lecture: Is Universal Health Care Coverage the Holy Grail?
7 May 2014
Join us on the evening of 9 June 2014 when OHE will welcome Professor Anne Mills of the London School of Hygiene and Tropical Medicine who will speak on Universal…
Towse at ISPOR: Macro HTA and Managed Entry Agreements
7 October 2014
…identified the issues and discussed the potential role of managed entry agreements (MEAs) and performance-based risk-sharing arrangements (PBRSAs). In essence, these measures allow a new medicine to be marketed while…
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
…the EU, the key factors influencing the future environment for generating and using relative effectiveness evidence are the: degree of EMA use of post-marketing authorization (post-launch) efficacy studies and adaptive…
OHE at HTAi Oslo: A New Drug Development Paradigm, a Framework for Developing Formularies in MICs, and the Effect of NICE Decisions Abroad
15 June 2015
This post summarises OHE’s activities at the upcoming HTAi meeting in Oslo, June 2015. Topics include the effect of NICE decisions abroad, a framework for developing formularies in MICs, a…
Two New Publications: ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty?’
6 September 2016
…Taiwanese perspective, explaining how conditional approval, with collection of post-marketing data alongside risk-sharing or pay-for-performance, is being explored locally. Finally, OHE’s Professor Adrian Towse explained how performance-based risk-sharing has been…